Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3403-3411

  Chen, Jiezhong ^a,b   Shao, Renfu ^c   Li, Li ^a   Xu, Zhi Ping ^a   Gu, Wenyi ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

5 FU; Apoptosis; BEZ 235; Cell death; Colon cancer HCT 116 cells; Layered double hydroxide (LDH); PI3K Akt mTOR

Indexed keywords

DACTOLISIB; FLUOROURACIL; HYDROXIDE; LAYERED DOUBLE HYDROXIDE; NANOPARTICLE; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HCT116 CELL LINE; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; COLON TUMOR; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; HYDROXIDES; IMIDAZOLES; NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84904413870     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S61633     Document Type: Article

References (52)

1. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. Int J Nanomedicine. 2011; 6: 1057-1068.
2. Thakral NK, Ray AR, Majumdar DK. Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Science Mater Med. 2010; 21(9): 2691-2699.
3. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229-237.
4. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006; 5: 20.
5. Liu W, Li X, Wong YS, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anti-cancer synergism. ACS Nano. 2012; 6(8)6578-6591.
6. Wang J-M, Xiao B-L, Zheng J-W, Chen H-B, Zou S-Q. Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer. World J Gastroenterol. 2007; 13(23): 3171-3175.
7. Hu YX, Chang J, Guo Y, Yuan XB, Kang CS, Pu P. Preparation and evaluation of 5-FU/PLGA/gene nanoparticles. Key Eng Mater. 2005; 288-289: 147-150.
8. Lo CL, Lin KM, Hsiue GH. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D, L-lactide)-g-poly(N-isopropyl acrylamide-co-methacrylic acid). J Control Release. 2005; 104(3): 477-488.
9. Joondeph BC, Peyman GA, Khoobehi B, Yue BY. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg. 1988; 19(4): 252-256.
10. Choi SJ, Oh JM, Chung HE, Hong SH, Kim IH, Choy JH. In vivo anticancer activity of methotrexate-loaded layered double hydroxide nanoparticles. Curr Pharm Des. 2013; 19(41): 7196-7202.
11. Zhu R, Wu X, Xiao Y, et al. Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line. Cancer Biother Radiopharm. 2013; 28(8): 579-587.
12. Xu ZP, Niebert M, Porazik K, et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J Control Release. 2008; 130(1): 86-94.
13. Xu ZP, Lu GC. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem. 2006; 78(9): 1771-1779.
14. Chen J, Shao R, Zhang XD, Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine. 2013; 8: 2677-2688.
15. Li L, Gu W, Chen J, Chen W, Xu ZP. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials. 2014; 35(10): 3331-3339.
16. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol. 2007; 25(18S): 4007.
17. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. European journal of Cancer. 1997; 33(2): 214-219.
18. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999; 17(5): 1349-1355.
19. Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 1989; 63(S6): 1036-1044.
20. Yin H, Xie F, Zhang J, et al. Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett. 2011; 306(1): 34-42.
21. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther. 2011; 19(11): 2040-2047.
22. Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano. 2013; 7(2): 994-1005.
23. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol. 2007; 25(18S): 4000.
24. Bhattacharya B, Akram M, Balasubramanian I, et al. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol Ther. 2012; 13(1): 34-42.
25. Chen J. Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer. Curr Cancer Drug Targets. 2013; 13(2): 117-120.
26. Bu Z, Ji J. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer. Curr Cancer Drug Targets. 2013; 13(2): 121-125.
27. Cho DC, Mier JW. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013; 13(2): 126-142.
28. Elfiky AA, Jiang Z. The PI3 kinase signaling pathway in prostate cancer. Curr Cancer Drug Targets. 2013; 13(2): 157-164.
29. Page C, Lin HJ, Jin Y, et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000; 20(1A): 407-416.
30. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001; 61(10): 3986-3997.
31. Roper J, Richardson MP, Wang WV, et al. The dual PI3K/mTOR inhibitor NVP-BEZ-235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One. 2011; 6(9): e25132.
32. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ-235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7): 1851-1863.
33. Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55(7): 1407-1412.
34. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 1995; 49(10): 1419-1426.
35. Gusella M, Frigo AC, Bolzonella C, et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009; 100(10): 1549-1557.
36. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008; 7(4): 12.
37. Choi SJ, Choy JH. Layered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicity. Nanomedicine (Lond). Jul 2011; 6(5): 803-814.
38. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011; 12(12): 1063-1070.
39. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ-235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010; 16(2): 530-540.
40. Wu P, Hu YZ. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem. 2010; 17(35): 4326-4341.
41. Chen J, Huang XF, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell HT29. J Gastrointest Oncol. 2011; 2(1): 27-33.
42. Chen J, Katsifis A, Hu C, Huang XF. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr Drug Discov Technol. 2011; 8(2): 119-125.
43. Bartucci M, Svensson S, Ricci-Vitiani L, et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr Relat Cancer. 2010; 17(3): 823-833.
44. Chen Y, Wang Z, Chang P, et al. The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int J Cancer. 2010; 127(1): 195-206.
45. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012; 367(17): 1596-1606.
46. Muller A, Bachmann E, Linning M, et al. Selective PI3K inhibition by BKMIZO and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastro intestinal cancer cell lines. Cancer Chemther Pharmacol. 2012; 69(6): 1601-1615.
47. Park S, Chapuis N, Bardet V, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia. 2008; 22(9): 1698-1706.
48. Schwab J, Antonescu C, Boland P, et al. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer research. 2009; 29(6): 1867-1871.
49. Chapuis N, Tamburini J, Green AS, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ-235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16(22): 5424-5435.
50. Santiskulvong C, Konecny GE, Fekete M, et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ-235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res. 2011; 17(8): 2373-2384.
51. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin invest. 2011; 121(4): 1231-1241.
52. Serra V, Scaltriti M, Prudkin L, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011; 30(22): 2547-2557.